Latest News
Anthropic recently signed a multibillion-dollar deal with Nvidia and Microsoft.
Via The Motley Fool · December 4, 2025
The CEO of one tech giant recently admitted that no company will be immune if the artificial intelligence (AI) bubble bursts.
Via The Motley Fool · December 4, 2025
One fund’s decision to walk away from Eastman Chemical may illuminate what’s really driving the stock’s prolonged slide.
Via The Motley Fool · December 4, 2025
We discuss a year as volatile as 2025 has been so far.
Via Talk Markets · December 4, 2025
The SCHD ETF has underperformed the market this year.
Via Talk Markets · December 4, 2025
The U.S. DOE just gave BWX stock a big boost.
Via The Motley Fool · December 4, 2025
The stock has climbed in the double-digits in recent years.
Via The Motley Fool · December 4, 2025
One detail in the latest earnings suggests why some deep-value investors may see more upside than the stock chart implies.
Via The Motley Fool · December 4, 2025
The digital advertising sector is seeing strong growth fueled by AI.
Via The Motley Fool · December 4, 2025
The company didn't report any positive news, but that doesn't mean investors don't have a reason to click the buy button.
Via The Motley Fool · December 4, 2025
This fund just made Axalta one of its largest bets—here’s why its latest results may explain the move.
Via The Motley Fool · December 4, 2025
Broadcom has all the ingredients to be the market's biggest chip winner next year.
Via The Motley Fool · December 4, 2025
ArrowMark’s sharp reduction in its Alight stake comes at a moment when the market is questioning whether the company can turn its consulting-heavy work into steadier recurring revenue, and that tension may say more about sentiment than about the strength of the platform itself.
Via The Motley Fool · December 4, 2025
One trader cited fiscal strength and an aggressive buyback plan.
Via Investor's Business Daily · December 4, 2025
Analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target, citing emerging gene therapies.
Via Benzinga · December 4, 2025
Via MarketBeat · December 4, 2025
New York, NY – December 4, 2025 – Wall Street is currently navigating a period of palpable tension and cautious optimism, with market volatility predominantly fueled by the fervent anticipation of imminent Federal Reserve interest rate cuts. As the year draws to a close, investors find themselves in a "holding breath" stance,
Via MarketMinute · December 4, 2025
Netflix is reportedly the primary bidder for the purchase of Warner Bros Discovery's assets, which raised investor concerns.
Via Benzinga · December 4, 2025
As of early December 2025, the U.S. stock market finds itself in a precarious yet optimistic position, with both the Dow Jones Industrial Average and the S&P 500 index hovering tantalizingly close to their all-time record highs. This remarkable resilience in equity valuations comes amidst a period of
Via MarketMinute · December 4, 2025
Using quantitative data and screening tools to create quantitative rules-driven portfolios that can be used for portfolio management or broadened to provide selection sets for active management.
Via Talk Markets · December 4, 2025
Via Benzinga · December 4, 2025
Chemical companies have been having a rough year.
Via The Motley Fool · December 4, 2025
Via MarketBeat · December 4, 2025
December 4, 2025 – Gold prices are holding remarkably firm, hovering near multi-month highs, as robust expectations for Federal Reserve interest rate cuts continue to dominate market sentiment. This resilience in the precious metal persists even amidst a backdrop of mixed US labor data, which, rather than dampening dovish bets, appears
Via MarketMinute · December 4, 2025